Fresenius SE & Co. KGaA (LON:0OO9)

Market Cap	21.61B -4.5%
Revenue (ttm)	20.05B +3.4%
Net Income	1.31B +35.3%
EPS	2.33 +35.3%
Shares Out	n/a
PE Ratio	16.49
Forward PE	11.69
Dividend	0.92 (2.37%)
Ex-Dividend Date	May 25, 2026

Volume	56,942
Open	44.61
Previous Close	44.79
Day's Range	44.05 - 44.93
52-Week Range	35.13 - 52.82
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod...

• Industry: Hospitals
• Founded: 1912
• Employees: 178,486
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0OO9

Financial Performance

In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 2, 2026

Data Sources Report a data error